![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Qorvo Biotechnologies Earns EUA for Rapid COVID-19 Antigen Test
Qorvo Biotechnologies Earns EUA for Rapid COVID-19 Antigen Test
![emergency use authorization approved](https://www.fdanews.com/ext/resources/test/Drug-Images4/emergency-use-authorization-EUA-approved.gif?t=1586211479&width=430)
Greensboro, N.C.-based Qorvo Biotechnologies has received FDA Emergency Use Authorization (EUA) for its rapid Omnia SARS-CoV-2 Antigen Test.
The test platform, which includes a portable test instrument and microfluidic cartridge, is authorized for using nasal swabs to qualitatively detect the presence of SARS-CoV-2 viral antigens.
The rapid test uses high-frequency acoustic wave sensors to deliver results in approximately 20 minutes.
Upcoming Events
-
21Oct